Chang H. Ahn, Ph.D.
Chief Executive Officer – Founder and Chairman
Dr. Chang H. Ahn is an internationally recognized drug development expert with over 20 years of experience in the fields of pharmacology and biotechnology. He founded Rexahn in 2001, and currently serves as the company’s Chairman and Chief Executive Officer. Prior, Dr. Ahn held dual positions as both Expert Regulatory Officer and Laboratory Chief at the FDA’s Center for Drug Evaluation and Research. While at the FDA, Dr. Ahn represented the agency in the fields of Antisense Oligonucleotide Therapeutics and Multi-Drug Resistance, and served a key role as both author and co-author of several FDA guidance documents. Before joining the FDA, Dr. Ahn carried out cancer research at the National Cancer Institute and Emory University’s School of Medicine. Dr. Ahn organized and chaired the U.S.-Korea Bio Business and Partnership Forum, of which Maryland State and Montgomery County are partners. He has also served as president of the Society of Biomedical Research since 2000.
Rick Soni, MBA
President and Chief Operating Officer
Rick Soni joined Rexahn in 2008 with over 20 years of sales, marketing, product planning and business development experience in the pharmaceutical industry. Prior to joining Rexahn, Mr. Soni held several leadership roles at Otsuka America Pharmaceuticals, Inc., with responsibility for commercial development, corporate strategy and execution of licensing and acquisition of therapeutics, diagnostics and medical devices. Previously, Mr. Soni has held a variety of management positions at Novartis and Schering-Plough. Mr. Soni has a BS from the University of Wisconsin-Madison and an MBA from Fairleigh Dickinson University.
Tae Heum (Ted) Jeong, MS
Sr. Vice President and Chief Business Officer
Ted Jeong has been Chief Financial Officer of Rexahn Pharmaceuticals since 2002. He has extensive experience as a venture capitalist. Prior to joining Rexahn, Mr. Jeong spent six years as senior investment manager at Hyundai Venture Investment Corporation, the leading Korean venture capital firm. At Hyundai, he managed the biotech investment team, and operated two specialized biotechnology funds. After joining Rexahn, Mr. Jeong’s accomplishments include securing public market listings, mergers, and successful fundraising efforts. Mr. Jeong holds a M.S. in Finance from Johns Hopkins University, a B.S. in Chemistry and an M.S., specializing in Biomedical Chemistry, from POSTECH, Pohang, Korea.